Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation
NCT: NCT06105541 · COMPLETED
Brief Summary
Investigate whether at-home transcutaneous auricular VNS (tAN: transcutaneous auricular neurostimulation) improves a battery of nine key physical and psychological symptoms of a group of hEDS (Hypermobile Ehlers-Danlos Syndrome \& Hypermobile Spectrum Disorder) patients (n=30) using a randomized, double blind, sham controlled design. The study team will collect clinical measures at baseline, after a two-week double-blind intervention phase, after a following two-week open-label phase and finally at three months post intervention. The study team will test patients in the following domains: pain, fatigue, sleep, anxiety, depression, quality of life, GI function, immune function and autonomic function.
Frequently Asked Questions
What is Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation?
Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation is a clinical trial registered under NCT06105541. Current status: COMPLETED.
What is the status of NCT06105541?
The current status of NCT06105541 (Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation) is: COMPLETED.
When did Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation start?
Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation started on 2023-07-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.